drugset

drugset / Trial / NCT05144386

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

NCT05144386 ↗

Phase 1 Completed 6 enrolled Excision BioTherapeutics

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a First in Human (FIH) study of EBT-101 administered IV to aviremic HIV-1 infected adults on stable antiretroviral therapy (ART).

Timeline

Start: 2022-01-24
Primary completion: 2024-11-14
Completion: 2024-11-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EBT-101	CRISPR / gene editing	—	Intravenous

Indications